Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

SOL hits record high after strong annual results

SOL's stock climbed in Milan to a new record high after strong results for the past fiscal year, with organic revenue up nine percent and improved margins. Berenberg raised its price target to €59.00 and reaffirmed its buy recommendation, but sees upside potential as nearly exhausted. Analysts highlight SOL's defensive market position, particularly the homecare division Vivisol and the technical gases business, noting that geopolitically driven helium shortages could offer short-term margin opportunities. » More on deraktionaer.de
SOL hits record high after strong annual results and dividend increase

SOL raised net revenue in 2025 by about 10% to €1.78 billion, EBITDA climbed to just under €452 million and EBIT to €270 million. Earnings per share were €1.84 (2024: €1.63) and the dividend is to be raised to €0.45 per share (previous year: €0.39). Analysts raised their estimates and price targets after the figures, and investors pushed the stock up about ten percent to new record levels. » More on deraktionaer.de

Historical dividends Dividends

All dividend metrics All metrics

In 2026, SOL Aktie has already paid €0.45 in dividends. The last payout was in May.

Financials

In the last quarter, SOL Aktie had revenue of €948.55m and net profit of €89.87m

(EUR)	June 2026	YoY
Revenue	948.55m	-
Gross profit	163.8m	-
Net profit	89.87m	-
EBITDA	241.76m	-

Fundamentals

Metric	Value
Market capitalization	€5.42bn
Number of shares	90.7m
52-week high/low	€64.00 - €44.85
Dividend yield	0.75%
Dividends TTM	€0.45
Beta	0.41
P/E ratio	31.31
PEG ratio	2.83
P/B ratio	4.58
P/S ratio	2.93

Company profile

SOL S.p.A. engages in the applied research, production, and marketing of technical and medical gases; and in home medical assistance and related medical equipment in Italy and internationally. The company offers technical and medical gases, including oxygen, nitrogen, argon, hydrogen, carbon and sulphur dioxide, acetylene, nitrous oxide, gas mixtures, high purity gases, food gases, and gaseous and liquid helium; gas for electronics; and ammonia and combustible gases for industrial use. It also provides home oxygen therapy, home mechanical ventilation, and aerosol therapy services, as well as the diagnosis and treatment of respiratory sleep disorders; services for artificial nutrition, insulin therapy with pumps, and immunotherapy, as well as services for the treatment of pain and Parkinson's disease; home healthcare and social care services; telemedicine and digital services; and healthcare aids. In addition, it provides medical devices; training services; InfoHealth SOLution, a web platform that allows to control plans, coordinate, and manage the activities; electromedical equipment services; hospital hygiene and environmental monitoring services; and ambulance management services. Further, it designs, constructs, and manages bio banks; distribution of medical and technical gases; produces and sells hydroelectric power; offers pre-and post-natal diagnostic screening services; produces and sells diagnostic systems; researches, develops, and markets products for research, diagnosis and clinical application in the hospital, environmental, veterinary and food sectors; and bioshipping services, as well as provides transfer, storage, and handling services of biological samples. Its products are used in the chemical, electronics, steel, metal, and food industries, as well as in environmental protection, and research and healthcare sectors. The company was founded in 1927 and is headquartered in Monza, Italy. SOL S.p.A. is a subsidiary of Gas and Technologies World BV.